Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell-focused technologies are designed to be used on their own or in combination with other immunotherapeutics.